Effectiveness and Safety of Intradermal Tranexamic Acid Injection as An Adjunctive Treatment for Melasma in Skin Type IV - V

• Status: Completed
• Trial end date: 2021-05-31
• Target enrollment: 0
• Participant gender: Female

Summary

A double-blind, randomized, split-face controlled trial of 34 female patients with melasma was conducted. All subject were randomized to receive either intradermal tranexamic acid or placebo injection on the right or the left side of their face.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Indonesia University
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• aged 18 to 60 years old

• Fitzpatrick skin type IV - V

• diagnosed with melasma

Exclusion Criteria:

• pregnancy and breastfeeding

• use of oral contraceptives within six months

• use of topical or systemic melasma therapy within two weeks

• history of superficial peeling within four weeks

• history of dermabrasion within six months

• use of photosensitizer drugs

• history of thrombosis or currently using antithrombotic or anticoagulant drugs

• history of TA allergy

• experiencing any COVID-19 symptoms